Details of the Drug

General Information of Drug (ID: DMAHSU0)

Drug Name

Selexipag

Synonyms

Selexipag; NS-304; 475086-01-2; Uptravi; NS 304; ACT-293987; UNII-5EXC0E384L; Selexipag(NS-304); ACT 293987; 5EXC0E384L; 2-(4-((5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)-N-(methylsulfonyl)acetamide; 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide; 2-(4-((5,6-Diphenylpyrazin-2-yl)(propan-2-yl)amino)butoxy}-n-(methanesulfonyl)acetamide; Selexipag [USAN:INN]; 2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-N-(methanesulfonyl)acetamide; Uptravi (TN)

Indication

Disease Entry	ICD 11	Status	REF
Pulmonary arterial hypertension	BB01.0	Approved	[1], [2]

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 1

Molecular Weight (mw)

496.6

Topological Polar Surface Area (xlogp)

3.8

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Clearance: The oral clearance of drug is 35 L/h [3]
Elimination: The elimination of drug is 93% via feces and 12% via urine [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 0.8 - 2.5 hours [4]
Metabolism: The drug is metabolized via the hydrolysis of the acylsulfonamide by the enzyme hepatic carboxylesterase 1 [5]

Chemical Identifiers

Formula: C26H32N4O4S
IUPAC Name: 2-[4-[(5,6-diphenylpyrazin-2-yl)-propan-2-ylamino]butoxy]-N-methylsulfonylacetamide
Canonical SMILES: CC(C)N(CCCCOCC(=O)NS(=O)(=O)C)C1=CN=C(C(=N1)C2=CC=CC=C2)C3=CC=CC=C3
InChI: InChI=1S/C26H32N4O4S/c1-20(2)30(16-10-11-17-34-19-24(31)29-35(3,32)33)23-18-27-25(21-12-6-4-7-13-21)26(28-23)22-14-8-5-9-15-22/h4-9,12-15,18,20H,10-11,16-17,19H2,1-3H3,(H,29,31)
InChIKey: QXWZQTURMXZVHJ-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 9913767
ChEBI ID: CHEBI:90844
CAS Number: 475086-01-2
DrugBank ID: DB11362
TTD ID: D0N2SR
INTEDE ID: DR1471
ACDINA ID: D00619

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Prostacyclin receptor (PTGIR)	TTOFYT1	PI2R_HUMAN	Agonist	[6]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2C8 (CYP2C8)_{Main DME}	DES5XRU	CP2C8_HUMAN	Substrate	[7]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Pulmonary arterial hypertension

ICD Disease Classification

BB01.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Prostacyclin receptor (PTGIR)	DTT	PTGIR	7.12E-02	-0.13	-0.33
Cytochrome P450 2C8 (CYP2C8)	DME	CYP2C8	2.93E-03	-2.19E-01	-4.49E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Selexipag (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Arn-509	DMT81LZ	Moderate	Increased metabolism of Selexipag caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[25]
Gilteritinib	DMWQ4MZ	Moderate	Decreased clearance of Selexipag due to the transporter inhibition by Gilteritinib.	Acute myeloid leukaemia [2A60]	[26]
Ag-221	DMS0ZBI	Moderate	Decreased clearance of Selexipag due to the transporter inhibition by Ag-221.	BCR-ABL1-negative chronic myeloid leukaemia [2A41]	[26]
Erdafitinib	DMI782S	Moderate	Decreased clearance of Selexipag due to the transporter inhibition by Erdafitinib.	Bladder cancer [2C94]	[27]
Tucatinib	DMBESUA	Moderate	Decreased clearance of Selexipag due to the transporter inhibition by Tucatinib.	Breast cancer [2C60-2C6Y]	[28]
PF-04449913	DMSB068	Moderate	Decreased clearance of Selexipag due to the transporter inhibition by PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[25]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Selexipag caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[29]
Ripretinib	DM958QB	Moderate	Decreased metabolism of Selexipag caused by Ripretinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[30]
Fostemsavir	DM50ILT	Moderate	Decreased clearance of Selexipag due to the transporter inhibition by Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[31]
Bempedoic acid	DM1CI9R	Moderate	Decreased clearance of Selexipag due to the transporter inhibition by Bempedoic acid.	Hyper-lipoproteinaemia [5C80]	[32]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Selexipag caused by PF-06463922 mediated induction of UGT.	Lung cancer [2C25]	[26]
Capmatinib	DMYCXKL	Moderate	Decreased clearance of Selexipag due to the transporter inhibition by Capmatinib.	Lung cancer [2C25]	[33]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Selexipag caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[26]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Selexipag caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[34]
Lasmiditan	DMXLVDT	Moderate	Decreased clearance of Selexipag due to the transporter inhibition by Lasmiditan.	Migraine [8A80]	[35]
Ozanimod	DMT6AM2	Moderate	Additive hypotensive effects by the combination of Selexipag and Ozanimod.	Multiple sclerosis [8A40]	[36]
Rucaparib	DM9PVX8	Moderate	Decreased clearance of Selexipag due to the transporter inhibition by Rucaparib.	Ovarian cancer [2C73]	[37]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Selexipag caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[38]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Selexipag caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[39]
Darolutamide	DMV7YFT	Moderate	Decreased clearance of Selexipag due to the transporter inhibition by Darolutamide.	Prostate cancer [2C82]	[40]
Tedizolid	DMG2SKR	Moderate	Decreased clearance of Selexipag due to the transporter inhibition by Tedizolid.	Skin and skin-structure infection [1F28-1G0Z]	[25]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Selexipag caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[26]
Pitolisant	DM8RFNJ	Moderate	Increased metabolism of Selexipag caused by Pitolisant mediated induction of CYP450 enzyme.	Somnolence [MG42]	[25]
Fostamatinib	DM6AUHV	Moderate	Decreased clearance of Selexipag due to the transporter inhibition by Fostamatinib.	Thrombocytopenia [3B64]	[41]
-----------


⏷ Show the Full List of 24 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Magnesium stearate	E00208	11177	lubricant
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
--------------------


⏷ Show the Full List of 7 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Selexipag 1.6 mg tablet	1.6 mg	Oral Tablet	Oral
Selexipag 0.6 mg tablet	0.6 mg	Oral Tablet	Oral
Selexipag 0.8 mg tablet	0.8 mg	Oral Tablet	Oral
Selexipag 1 mg tablet	1 mg	Oral Tablet	Oral
Selexipag 1.2 mg tablet	1.2 mg	Oral Tablet	Oral
Selexipag 0.2 mg tablet	0.2 mg	Oral Tablet	Oral
Selexipag 0.4 mg tablet	0.4 mg	Oral Tablet	Oral
Selexipag 1.4 mg tablet	1.4 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7552).
2	ClinicalTrials.gov (NCT01106014) Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial. U.S. National Institutes of Health.
3	An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
6	Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J. 2012 Oct;40(4):874-80.
7	FDA Label of Uptravi. The 2020 official website of the U.S. Food and Drug Administration.
8	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
9	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
10	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
11	Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
12	Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
13	Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
14	PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
15	Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
16	Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an experience-based review. Am Heart J. 2009 Apr;157(4):625-35.
17	Novel signaling pathways promote a paracrine wave of prostacyclin-induced vascular smooth muscle differentiation. J Mol Cell Cardiol. 2009 May;46(5):682-94.
18	Palmitoylation of the human prostacyclin receptor. Functional implications of palmitoylation and isoprenylation. J Biol Chem. 2003 Feb 28;278(9):6947-58.
19	Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806.
20	Prostaglandin I2 IP Receptor Agonist, Beraprost, Prevents Transient Global Cerebral Ischemia Induced Hippocampal CA1 Injury in Aging Mice. J Neurol Disord. 2014;2:1000174.
21	Specific binding of the new stable epoprostenol analogue beraprost sodium to prostacyclin receptors on human and rat platelets. Arzneimittelforschung. 1989 Apr;39(4):495-9.
22	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
23	Protective effect of a prostaglandin I2 analog, TEI-7165, on ischemic neuronal damage in gerbils. Brain Res. 1997 Sep 26;769(2):321-8.
24	Pharmacokinetics of intravenous ataprost alfadex, a new prostaglandin I2 analog in healthy volunteers. Int J Clin Pharmacol Ther Toxicol. 1993 Aug;31(8):373-5.
25	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
26	Cerner Multum, Inc. "Australian Product Information.".
27	Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
28	Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
29	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
30	Product Information. Uptravi (selexipag). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
31	Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
32	Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
33	Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
34	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
35	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
36	Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
37	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
38	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
39	Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
40	Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
41	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.